Keryx Biopharmaceuticals, Inc. (KERX)

1 member of Congress has disclosed 8 trades in Keryx Biopharmaceuticals, Inc. (KERX) via STOCK Act filings. The most recent disclosure was a purchase by Debbie Wasserman Schultz on 10 February 2017. Aggregate disclosed activity totals roughly $64K in purchases (midpoint estimates from bracketed disclosure amounts).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for KERX
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for KERX

5 transactions
Compliance: 50%
Debbie Wasserman Schultz10 Feb 201715 Feb 2017PurchaseStock$1,001 - $15,000N/A
Debbie Wasserman Schultz10 Feb 20172 Aug 2018PurchaseStock$1,001 - $15,000N/A
Debbie Wasserman Schultz12 Dec 20164 Aug 2017PurchaseStock$1,001 - $15,000N/A
Debbie Wasserman Schultz12 Dec 201611 Aug 2017PurchaseStock$1,001 - $15,000N/A
Debbie Wasserman Schultz12 Dec 201611 Aug 2017PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Stock Overview

Market Data

Market Cap

$0

Volume

0

Beta

1.82

P/E Ratio

-4.43

Fundamentals

EPS

$-0.76

Div. Yield

-

Open

$3.36

Day Range

$3.36 – $3.36

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
IPO Date
2000-07-28

Earnings

Recent Quarters

Q2 201830 Sept
EPS$-0.14
Miss 37.4%
Q1 201830 Jun
EPS$-0.18
Beat 19.7%
Q4 201731 Mar
EPS$-0.18
Miss 23.8%
Q3 201731 Dec
EPS$-0.26
Beat 10.6%
Q2 201730 Sept
EPS$-0.20
Beat 20.2%
Q1 201730 Jun
EPS$-0.77
Beat 6.4%
Q4 201631 Mar
EPS$-0.21
Beat 5.6%
Q3 201631 Dec
EPS$-0.32
Beat 28.0%
Q2 201630 Sept
EPS$-0.39
Beat 24.1%
Q1 201630 Jun
EPS$-0.42
Miss 62.9%
Q4 201531 Mar
EPS$-0.39
Miss 61.8%
Q3 201531 Dec
EPS$-0.36
Miss 90.8%
Q2 201530 Sept
EPS$-0.29
Beat 8.2%
Q1 201530 Jun
EPS$-0.26
Beat 25.8%
Q4 201431 Mar
EPS$-0.28
Miss 68.1%
Q3 201431 Dec
EPS$-0.44
Miss 9.8%
Q2 201430 Sept
EPS$-0.38
Beat 12.7%
Q1 201430 Jun
EPS$-0.24
Beat 26.4%
Q4 201331 Mar
EPS$-0.15
Miss 17.4%
Q3 201331 Dec
EPS$-0.21
Beat 16.6%
Q2 201330 Sept
EPS$-0.19
Miss 25.9%
Q1 201330 Jun
EPS$-0.14
Beat 14.9%
Q4 201231 Mar
EPS$-0.03
Beat 15.9%
Q3 201231 Dec
EPS$-0.09
Beat 29.7%
Q2 201230 Sept
EPS$-0.08
Miss 20.0%
Q1 201230 Jun
EPS$-0.02
Beat 3.2%
Q4 201131 Mar
EPS$-0.13
Miss 9.2%
Q3 201131 Dec
EPS$-0.12
Miss 65.6%
Q2 201130 Sept
EPS$-0.15
Miss 78.5%
Q1 201130 Jun
EPS$-0.05
Miss 65.9%
Q4 201031 Mar
EPS$-0.10
Miss 47.5%
Q3 201031 Dec
EPS$-0.09
Beat 23.0%
Q2 201030 Sept
EPS$-0.10
Beat 10.8%
Q1 201030 Jun
EPS$-0.09
Miss 17.3%
Q4 200931 Mar
EPS$-0.07
Miss 66.1%
Q3 200931 Dec
EPS$-0.08
Miss 22.9%
Q2 200930 Sept
EPS$0.01
Beat 8.3%
Q1 200930 Jun
EPS$0.29
Miss 15.1%
Q4 200831 Mar
EPS$0.01
Beat 10.3%
Q3 200831 Dec
EPS$-0.08
Miss 12.6%
Q2 200830 Sept
EPS$-0.15
Miss 3.2%
Q1 200830 Jun
EPS$-0.17
Miss 60.1%
Q4 200731 Mar
EPS$-0.79
Miss 22.0%
Q3 200731 Dec
EPS$-0.67
Beat 23.2%
Q2 200730 Sept
EPS$-0.45
Miss 67.3%
Q1 200730 Jun
EPS$-0.45
Beat 12.9%
Q4 200631 Mar
EPS$-0.50
Beat 22.3%
Q3 200631 Dec
EPS$-0.42
Beat 20.7%
Q2 200630 Sept
EPS$-0.42
Miss 107.0%
Q1 200630 Jun
EPS$-0.41
Miss 32.7%
Q4 200531 Mar
EPS$-0.51
Beat 9.4%
Q3 200531 Dec
EPS$-0.24
Miss 89.2%
Q2 200530 Sept
EPS$-0.19
Miss 32.5%
Q1 200530 Jun
EPS$-0.19
Miss 2.2%
Q4 200431 Mar
EPS$-0.15
Miss 107.3%
Q3 200431 Dec
EPS$-0.15
Beat 15.7%
Q2 200430 Sept
EPS$-0.11
Beat 17.4%
Q1 200430 Jun
EPS$-0.11
Beat 22.5%
Q4 200331 Mar
EPS$-0.78
Beat 20.6%
Q3 200331 Dec
EPS$-0.08
Miss 48.4%
Q2 200330 Sept
EPS$-0.07
Beat 18.4%
Q1 200330 Jun
EPS$-0.07
Beat 8.2%
Q4 200231 Mar
EPS$-0.19
Beat 28.6%
Q3 200231 Dec
EPS$-0.14
Miss 40.1%
Q2 200230 Sept
EPS$-0.15
Beat 29.4%
Q1 200230 Jun
EPS$-0.12
Miss 65.1%
Q4 200131 Mar
EPS$-0.18
Beat 13.5%
Q3 200131 Dec
EPS$-0.13
Miss 33.0%
Q2 200130 Sept
EPS$-0.07
Beat 9.3%
Q1 200130 Jun
EPS$-0.17
Beat 8.0%
Q4 200031 Mar
EPS$-0.12
Miss 30.1%
Q3 200031 Dec
EPS$-0.15
Beat 9.1%
Q2 200030 Sept
EPS$-0.17
Beat 24.0%
Q1 200030 Jun
EPS$-0.40
Beat 27.2%
Q4 199931 Mar
EPS$-0.30
Miss 46.7%

4 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about KERX

Which members of Congress have traded KERX?
1 member of Congress has disclosed 8 trade in Keryx Biopharmaceuticals, Inc. (KERX) under the STOCK Act: Debbie Wasserman Schultz.
When was KERX most recently disclosed by Congress?
The most recent KERX disclosure was a purchase by Debbie Wasserman Schultz on 10 February 2017.
What is the total disclosed congressional trading volume for KERX?
Members of Congress have disclosed approximately $64K in KERX purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in KERX?
This KERX page updates as soon as new STOCK Act disclosures are filed for Keryx Biopharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.